Health Catalyst, Inc. (NASDAQ:HCAT) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Health Catalyst, Inc. (NASDAQ:HCAT) have earned a consensus rating of “Moderate Buy” from the ten analysts that are covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $10.60.

A number of brokerages have recently issued reports on HCAT. Piper Sandler reaffirmed an “overweight” rating and set a $12.00 price target (up previously from $11.00) on shares of Health Catalyst in a report on Tuesday, November 26th. Citigroup cut their target price on shares of Health Catalyst from $10.50 to $10.00 and set a “buy” rating for the company in a research report on Friday, January 10th. KeyCorp raised Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 price target on the stock in a report on Wednesday, January 8th. Royal Bank of Canada reduced their price objective on Health Catalyst from $9.00 to $7.00 and set a “sector perform” rating for the company in a research report on Wednesday, January 15th. Finally, Canaccord Genuity Group dropped their target price on Health Catalyst from $11.00 to $10.00 and set a “buy” rating on the stock in a research report on Tuesday, January 21st.

Insiders Place Their Bets

In related news, CFO Jason Alger sold 19,599 shares of the business’s stock in a transaction on Friday, December 6th. The stock was sold at an average price of $8.32, for a total transaction of $163,063.68. Following the completion of the transaction, the chief financial officer now owns 86,712 shares in the company, valued at $721,443.84. The trade was a 18.44 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Duncan Gallagher sold 4,500 shares of the company’s stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $6.98, for a total value of $31,410.00. Following the completion of the transaction, the director now directly owns 74,438 shares in the company, valued at $519,577.24. This trade represents a 5.70 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 81,169 shares of company stock valued at $629,068 over the last ninety days. 2.50% of the stock is owned by insiders.

Institutional Investors Weigh In On Health Catalyst

A number of institutional investors and hedge funds have recently bought and sold shares of HCAT. Quest Partners LLC purchased a new position in Health Catalyst during the third quarter valued at approximately $34,000. nVerses Capital LLC purchased a new position in shares of Health Catalyst in the 3rd quarter valued at $59,000. Stoneridge Investment Partners LLC bought a new position in shares of Health Catalyst in the 4th quarter worth $77,000. Quadrature Capital Ltd purchased a new stake in shares of Health Catalyst during the 3rd quarter worth $84,000. Finally, Harbor Capital Advisors Inc. boosted its position in Health Catalyst by 21.3% during the third quarter. Harbor Capital Advisors Inc. now owns 11,764 shares of the company’s stock valued at $96,000 after purchasing an additional 2,064 shares in the last quarter. 85.00% of the stock is owned by institutional investors.

Health Catalyst Trading Up 3.8 %

HCAT opened at $5.70 on Friday. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32. Health Catalyst has a 52 week low of $5.32 and a 52 week high of $10.31. The stock has a market cap of $346.83 million, a PE ratio of -4.22 and a beta of 1.34. The business has a 50 day moving average of $6.86 and a 200-day moving average of $7.43.

Health Catalyst (NASDAQ:HCAT) last released its earnings results on Wednesday, November 6th. The company reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. The company had revenue of $76.40 million during the quarter, compared to analysts’ expectations of $76.27 million. During the same period in the prior year, the company posted ($0.22) earnings per share. The company’s revenue was up 3.5% on a year-over-year basis. Equities research analysts predict that Health Catalyst will post -0.33 earnings per share for the current fiscal year.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.